Beijing, China, June 26 – CPHI China 2025 successfully concluded at the Shanghai New International Expo Centre(SNIEC). The three-day event gathered leading forces from the global pharmaceutical industry, with a total exhibition area surpassing 230,000 square meters, attracting over 3,500 pharmaceutical companies from around the world. The exhibition showcased the latest achievements in pharmaceutical raw materials, formulation technologies, and biopharmaceuticals, providing an efficient platform for communication and collaboration, further promoting innovation and development across the global pharmaceutical supply chain.

Gan & Lee Pharmaceuticals (hereinafter referred to as Gan & Lee, stock code: 603087.SH) has been consistently exhibiting at the event with a custom-designed booth. Gan & Lee utilized a "Product Display and Business Negotiation" dual-zone booth model, presenting a comprehensive range of our insulin products and delivery devices, while also engaging in international business negotiations. This fully demonstrated Gan & Lee’s competitive advantages in the entire industrial chain, from innovative R&D to our global expansion strategy.

Gan & Lee showcased its core products at the event, featuring long-acting, rapid-acting, premixed, and human insulin injections, along with complementary devices including prefilled pens, reusable pens, and single-use needles. This allowed professional visitors to gain a more comprehensive and direct understanding of Gan & Lee’s product portfolio. During the event, Gan & Lee's booth attracted representatives from over 100 companies across regions including Europe, America, Asia, Latin America, Africa, and more, facilitating in-depth discussions on product development, registration, market dynamics, collaboration prospects, and localized production. Preliminary agreements were reached on several projects, accelerating Gan & Lee’s internationalization efforts and laying a stronger foundation for global market expansion.

Mr. Kai Du, Executive Vice President and Chief Commercial Officer (CCO) of Gan & Lee, stated: "We are committed to providing high-quality and convenient treatment solutions for diabetic patients worldwide through continuous R&D innovation. This exhibition, which showcases our product portfolio and deepens international business collaboration, highlights our innovation capabilities and global strategy. We believe that with our strong expertise in the diabetes field, extensive product pipeline, and expansive global collaboration network, Gan & Lee is well-positioned to play a significant role in the global diabetes treatment market and benefit more patients."

During the exhibition, Gan & Lee also received important recognition at the industry's authoritative award ceremony. On the evening of the first day of the event, Mr. Shuai Jun, Deputy Director of the International Business Department for the Eurasian region, represented the company at the "CPHI Celebration Awards & Networking Party." The awards ceremony aimed to honor innovative benchmarks and empower high-quality development. Thanks to its sustained independent innovation and breakthrough R&D achievements, Gan & Lee stood out among numerous candidates and won the "R&D Innovation Awards" at this exhibition. This international honor further underscores Gan & Lee’s excellent performance and industry influence at the event.

At CPHI China 2025, Gan & Lee presented a comprehensive display under the theme of "R&D Innovation - Global Supply - Local Empowerment," showcasing international solutions for its insulin product series. The company highlighted its biosimilar technology transfer and localized production solutions, which provide customized support for regulatory market access needs in different regions, demonstrating the ability of Chinese companies to meet the global demand for diabetes treatment. By building a full value-chain cooperation system covering R&D, production, and supply, Gan & Lee is committed to transforming China's diabetes management experience into high-quality solutions adapted to various healthcare environments worldwide, continuously improving the accessibility of innovative biologics on a global scale.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.